DE68924850D1 - Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. - Google Patents

Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.

Info

Publication number
DE68924850D1
DE68924850D1 DE68924850T DE68924850T DE68924850D1 DE 68924850 D1 DE68924850 D1 DE 68924850D1 DE 68924850 T DE68924850 T DE 68924850T DE 68924850 T DE68924850 T DE 68924850T DE 68924850 D1 DE68924850 D1 DE 68924850D1
Authority
DE
Germany
Prior art keywords
cellular immunological
vaccinates
immunological reagents
specific binding
binding ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68924850T
Other languages
English (en)
Other versions
DE68924850T2 (de
Inventor
Daniel Zimmerman
Donald Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cel Sci Corp
Original Assignee
Cell Med Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Med Inc filed Critical Cell Med Inc
Application granted granted Critical
Publication of DE68924850D1 publication Critical patent/DE68924850D1/de
Publication of DE68924850T2 publication Critical patent/DE68924850T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE68924850T 1988-06-14 1989-06-12 Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. Expired - Fee Related DE68924850T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20638188A 1988-06-14 1988-06-14
PCT/US1989/002503 WO1989012458A1 (en) 1988-06-14 1989-06-12 Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same

Publications (2)

Publication Number Publication Date
DE68924850D1 true DE68924850D1 (de) 1995-12-21
DE68924850T2 DE68924850T2 (de) 1996-10-10

Family

ID=22766120

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924850T Expired - Fee Related DE68924850T2 (de) 1988-06-14 1989-06-12 Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.

Country Status (8)

Country Link
US (2) US5652342A (de)
EP (1) EP0420913B1 (de)
JP (1) JPH03504975A (de)
AT (1) ATE130197T1 (de)
AU (1) AU633007B2 (de)
CA (1) CA1339339C (de)
DE (1) DE68924850T2 (de)
WO (1) WO1989012458A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
EP0839536A1 (de) * 1989-10-27 1998-05-06 Arch Development Corporation Methoden und Zusammensetzungen zur Förderung der Immunverstärkung
CA2049931A1 (en) * 1990-01-24 1991-07-25 Barbara P. Wallner Lfa-3 as a vaccine adjuvant
GR1001220B (el) * 1990-08-06 1993-06-21 Praxis Biolog Inc Φορεις κυτοκινης και ορμονης για συζευγμενα εμβολια.
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
IL102964A0 (en) * 1991-08-26 1993-01-31 Cytel Corp Hla-restricted hepatitis b virus ctl epitopes
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
ATE204300T1 (de) * 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
JPH10503379A (ja) * 1994-07-29 1998-03-31 デイド・インターナショナル・インコーポレーテッド Ｍｈｃ複合体およびその用途
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
CA2232344C (en) 1995-10-20 2005-04-05 University Of Nebraska Board Of Regents Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
US6224870B1 (en) 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
AU729406B2 (en) * 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6103239A (en) * 1996-08-09 2000-08-15 Cel-Sci Corporation Modified HGP-30 heteroconjugates, compositions and methods of use
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
US5990286A (en) * 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
AU8513798A (en) 1997-07-25 1999-02-16 Trustees Of Boston University Methods and compositions for determining species of bacteria and fungi
US6673538B1 (en) 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
CA2304206A1 (en) 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6572860B1 (en) 1997-09-30 2003-06-03 Cel-Sci Corporation Immunogenic conjugated polypeptide for treatment of herpes simplex virus
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
DE69739210D1 (de) * 1997-12-16 2009-02-26 Univ Zuerich Diagnostik für übertragbare spongiforme Enzephalopathie
AU770319C (en) 1998-05-04 2004-11-25 Point Therapeutics, Inc. Hematopoietic stimulation
WO1999062914A1 (en) 1998-06-05 1999-12-09 Point Therapeutics, Inc. Cyclic boroproline compounds
DE69918146T2 (de) * 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6995237B1 (en) * 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
JP2003514828A (ja) 1999-10-27 2003-04-22 セル−サイ・コーポレーシヨン 自己免疫および移植組織に関連する宿主対移植片症状の処置に有用なペプチド構築物の調製法および組成物
EP1598370A3 (de) * 1999-10-27 2006-05-10 Cel-Sci Corporation Präparationsverfahren und Verbindungen von Peptidkonstrukten die sich zur Behandlung von autoimmun- bzw. transplantationsbedingten Pathogenesen eignen
JP2002034594A (ja) * 2000-07-24 2002-02-05 National Institute Of Advanced Industrial & Technology 生細胞の検出方法
DK1412487T3 (da) * 2001-07-30 2010-08-30 Meso Scale Technologies Llc Assayelektroder der har immobiliserede lipid/proteinlag og fremgangsmåder til at fremstille og anvende disse
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
EP1551449B1 (de) * 2002-07-12 2010-10-06 The Johns Hopkins University Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
EP1868642B1 (de) * 2005-03-18 2013-05-08 Cytos Biotechnology AG Katzenallergen-fusionsproteine und ihre verwendung
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
WO2014176604A1 (en) 2013-04-26 2014-10-30 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465A1 (de) 2007-07-03 2020-03-11 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US11041013B2 (en) 2008-03-14 2021-06-22 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CA2868123A1 (en) 2012-03-23 2013-09-26 The University Of Queensland Immunomodulatory agent and uses therefor
CA3031028C (en) * 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
CA3070297A1 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
US20220218806A1 (en) 2019-05-11 2022-07-14 CRL-SCI Corporation Peptides and conjugates for treatment of arthritis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006916B1 (de) * 1977-09-28 1981-07-08 National Research Development Corporation MHC-Antigene enthaltende immunologische Präparate und deren Herstellung
US4400376A (en) * 1979-03-27 1983-08-23 National Research Development Corporation Immunological preparations
ZA831854B (en) * 1982-03-26 1984-01-25 Biogen Nv Small peptides with the specificity of foot and mouth disease viral antigens
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
EP0177023A3 (de) * 1984-10-02 1987-08-12 The Calpis Food Industry Co., Ltd. An eine Substanz gebundenes Komplement-Bestandteil C1q
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
JP2633881B2 (ja) * 1986-06-30 1997-07-23 マサチューセッツ インスティテュート オブ テクノロジー 免疫調節組成物及びそれらの使用
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4835255A (en) * 1987-03-26 1989-05-30 Yale University T-cell membrane protein

Also Published As

Publication number Publication date
US5652342A (en) 1997-07-29
DE68924850T2 (de) 1996-10-10
WO1989012458A1 (en) 1989-12-28
AU633007B2 (en) 1993-01-21
EP0420913A4 (en) 1991-09-11
US6096315A (en) 2000-08-01
ATE130197T1 (de) 1995-12-15
EP0420913B1 (de) 1995-11-15
CA1339339C (en) 1997-08-19
EP0420913A1 (de) 1991-04-10
AU3777989A (en) 1990-01-12
JPH03504975A (ja) 1991-10-31

Similar Documents

Publication Publication Date Title
DE68924850D1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
SE8202012L (sv) Humaninterferon-beslektade peptider, antigener, antikroppar och forfarande for framstellning derav
DE3879000T2 (de) Immunoassaymethode zum auffinden von antikoerpern zu antigenen.
ES445768A1 (es) Metodo de preparacion de un reactivo en fase solida para usoen el radio inmunoensayo de antigenos y anticuerpos y de realizacon del radio inmunoensayo.
SE8003732L (sv) Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner
ATE37095T1 (de) Fluoreszenz-untersuchungsverfahren zur bluttypenbestimmung.
ATE113962T1 (de) Von polypeptiden induzierte monoklonale antikörper gegen oncoproteine.
NL181461C (nl) Werkwijze en reagenskit voor het bepalen van antigenen, antilichamen of antigeen-antilichaam-complexen of -conjugaten.
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
ES2176347T3 (es) Modulacion de la respuesta inmune.
ES8304314A1 (es) "metodo y su correspondiente aparato para el ensayo de anticuerpos con respecto a antigenos solubles".
EP0352722A3 (de) Bindungstests für Adenocarcinoma-Antigen und Reagenzien
SE8300320D0 (sv) Monoclonal antibody formulation for diagnostic use
ATE217086T1 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
ES2130257T3 (es) Nuevos compuestos y conjugados.
DE3280319D1 (de) Fuer endotoxine spezifische antikoerper.
NO168746C (no) Antistoff som er istand til aa binde histamin
ATE80467T1 (de) Immuntestverfahren.
EP0158291A3 (de) Verfahren zur Reinigung von karzinoembryonischem Antigen und Verfahren zur Herstellung eines monoklonalen Antikörpers, der mit karzinoembryonischem Antigen reagiert
DE3569161D1 (en) Process for assaying atl virus antibody and reagent therefore
ES8401261A1 (es) Soportes de materia plastica revestidos de un segundo anticuerpo.
DK414386A (da) Monoklonalt antistof, cellelinje til fremstilling deraf og antistoffets anvendelse
DK324287D0 (da) Antistof mod koensspecifikt antigen
EP0407605A4 (en) Reagent for detecting antibody corresponding to acid-fast bacterium antigen and application thereof
JPS5386014A (en) Quantitative analysis of antigen and antibody

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CEL-SCI CORP., ALEXANDRIA, VA., US

8339 Ceased/non-payment of the annual fee